SCHIZOPHRENIA RESEARCH IN GLASGOW AND BEYOND Nagore Penades - PowerPoint PPT Presentation

BIPOLAR, DEPRESSION AND SCHIZOPHRENIA RESEARCH IN GLASGOW AND BEYOND Nagore Penades Consultant in General Adult Psychiatry Mental Health Partnership Researcher

Commercial/Sponsored Studies A phase II randomized, double-blinded, placebo- controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week treatment period in patients with schizophrenia

Commercial/Sponsored Studies About the Compound : BI 425809 is a GLYT1 inhibitor. Inhibition of GLYT1 increases the concentration of the NMDA receptor co-activator Glycine in the synaptic cleft, which may lead to improvement of negative and cognitive symptoms in patients with schizophrenia and to cognitive improvement in patients with Alzheimer’s Disease.

Commercial/Sponsored Studies Main Inclusion Criteria  Male or Female 18-50 years of age  Diagnosis of Schizophrenia  Stable with no hospital admissions for 3 months  Medically stable for over 4 weeks.  PANSS- No more than “moderate severe” rating on positive items P1,P3-P7.  Must have an identified informant

Commercial/Sponsored Studies Research Team - Claire Matrunola, Research Assistant - Murray Sutherland, Research Nurse - Matt Turner, ST5 - Akkshay Iyer, ST6 - You?

Academic Collaboration ATP Trial: Treatment Resistant Depression A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS- penetrant P2X7 receptor antagonist, in people with major depressive disorder, an incomplete response to monoaminergic antidepressant drugs, and a biomarker profile predictive of active P2X7 signalling. UK multicentre Welcome trust sponsored academic- industry collaboration.

Academic Collaboration ATP Trial: Treatment Resistant Depression Aim: To evaluate the efficacy of JNJ-54175446, compared to placebo as an adjunctive antidepressant therapy for people with incomplete response to conventional antidepressant drugs and a biomarker profile predictive of active P2X7 signalling. Assessment:  Objective and subjective evaluation of MMD: MADRS  Biomarkers for peripheral inflammation (e.g. gene expression in peripheral blood mononuclear cell)  Brain imaging.

Academic Collaboration ATP Trial: Treatment Resistant Depression Inclusion Criteria:  HDRS17 at screening ≥ 17.  Currently being treated with one antidepressant drug from one of three classes of monoaminergic antidepressant: SSRI, SNRI or TCA  Antidepressant treatment must have been prescribed at an adequate dose, and for at least 6 weeks and no more than 24 months.  In addition, patients may receive stable augmentation therapy with mirtazapine, low-dose quetiapine (≤ 150 mg/day), or low-dose amitriptyline (<50 mg/day).

Academic Collaboration ATP Trial: Treatment Resistant Depression Research Team - Professor J Cavanagh and Team - Murray Sutherland, Research Nurse, CRF - Louise Beattie, Research Assistant - Akkshay Iyer, ST6 - You?

Pharmacogenomics of response to Lithium “Towards precision medicine for bipolar disorder: a pilot study of genetic and non-genetic influences on lithium responsiveness” RQ1.-To what extend does polygenic loading for mood instability influence response to lithium? RQ2.-Does a history of childhood adversity attenuate any observed association between polygenic loading for mood instability and lithium response?

Pharmacogenomics of response to Lithium “Towards precision medicine for bipolar disorder: a pilot study of genetic and non- genetic influences on lithium responsiveness”  200 Scottish participants with diagnosis of Bipolar Disorder  Alda and ACE questionnaires  GWAS

Pharmacogenomics of response to Lithium Research Team - Professor D Smith - Nagore Penades - Jacquie McTaggart, Research Nurse, CRF - Akkshay Iyer, Matt Turner - You?

Tasks - Recruitment and Consenting - Study interviews - Rating Scales/Questionnaires:  Alda questionnaire/ACEs questionnaire  MINI, PANNS, SCoRs, MCCB..... Time Scales: - Currently recruiting Days: - Mainly Fridays

Covid-Proof Projects 1- Interventional Study: CBT based digital depression and anxiety groups for care workers 2- Outcome Evaluation Study- Digital vs. Traditional groups 3-MyPsych App Evaluation study

Covid-Proof Projects Team: Ever growing Time Scales: Ready to start Tasks: Study design and protocol writing • Funding applications • Data analysis • Paper writing • Day of the Week: Flexible

Thank you